HIKMA PHARMACEUTIC.LS-,10/  GB00B0LCW083  /

Hikma Pharmaceuticals plc is a multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three core businesses segments: Branded, Injectables and Generics, based principally in the Middle East and North Africa ("MENA") as well as in the United States and Europe. Branded is the largest business of the group which focuses on the MENA region. Hikma develops, manufactures, and markets branded generics and a portfolio of in-licensed products, many of which are still patent protected. They are manufacturing strong anti-infective franchise and increasing focus on cardiovascular, diabetes and central nervous system (CNS) products. The Injectables business sells specialised generic injectable products globally, with state-of-the-art manufacturing facilities in the US and Europe. The Generics business sells non-injectable generic products in the US, with an increasingly differentiated portfolio and pipeline. In Februar 2016 Hikma acquired Roxane Laboratories Inc. and Boehringer Ingelheim Roxane Inc. from Boehringer Ingelheim. Hikma Pharmaceuticals was established 1978 in Amman, Jordan and is headquartered in London, UK.